Target intelligence / Profile preview

ATP-binding cassette sub-family C member 8 (Sulfonylurea receptor 1) (SUR1)

Target
SUR1
Molecular classification
ATP-binding cassette transporter, Ion channel regulatory subunit, Potassium channel
01

Overview

ATP-binding cassette sub-family C member 8, commonly known as Sulfonylurea receptor 1 (SUR1), is a key regulatory subunit of the ATP-sensitive potassium (KATP) channel found in pancreatic beta-cells [1][3]. It assembles with the inward-rectifier potassium channel subunit Kir6.2 to form a hetero-octameric complex that acts as a metabolic sensor, linking the cell's metabolic state to its electrical activity [4]. When blood glucose levels rise, the resulting increase in the intracellular ATP/ADP ratio triggers the closure of these channels, leading to membrane depolarization and subsequent insulin secretion [5]. Dysregulation of this protein due to genetic mutations is a primary cause of disorders such as congenital hyperinsulinism and various forms of neonatal diabetes [1]. SUR1 is the pharmacological target for sulfonylureas and meglitinides, which promote insulin release in type 2 diabetes by inducing channel closure [2]. Conversely, channel openers like diazoxide are used to treat hyperinsulinemia by maintaining the channel in an open state, thereby inhibiting insulin exocytosis [4]. Sources: [1] UniProt Q09428; [2] StatPearls (Sulfonylureas); [3] NCBI Gene 6833; [4] Nature (2006) 440:440-448; [5] StatPearls (Physiology, Insulin).

Other names
ABCC8Sulfonylurea receptor 1SUR1MRP8PHHIHRINSABC36HHF1
02

Mechanism of action

Sulfonylureas and meglitinides bind to the SUR1 subunit of the KATP channel, causing the channel to close. This closure leads to membrane depolarization, opening of voltage-gated calcium channels, and subsequent insulin exocytosis [2][5]. Conversely, potassium channel openers like diazoxide bind to SUR1 to keep the channel open, inhibiting insulin secretion [1][4].

03

Biological functions

Insulin secretion regulationGlucose homeostasisPotassium ion transportMetabolic sensing
04

Disease associations

Type 2 diabetes mellitusCongenital hyperinsulinismNeonatal diabetes mellitusHyperinsulinemic hypoglycemia
05

Safety considerations

HypoglycemiaWeight gainSecondary treatment failurePotential cardiovascular risks with non-selective sulfonylureas
06

Interacting drugs

Glibenclamide

7 more in the full profile.

07

Biomarkers

Blood glucose levelsC-peptide levelsSerum insulin levelsABCC8 genetic variants

Beyond the preview

Go deeper on ATP-binding cassette sub-family C member 8 (Sulfonylurea receptor 1) (SUR1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP-binding cassette sub-family C member 8 (Sulfonylurea receptor 1) (SUR1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call